Related Experiment Video
Updated: Nov 21, 2025

Performing and Processing FNA of Anterior Fat Pad for Amyloid
Published on: October 30, 2010
Cardiac Amyloidosis for the Primary Care Provider: A Practical Review to Promote Earlier Recognition of Disease
Kathleen W Zhang1, Srilakshmi Vallabhaneni1, Jose A Alvarez-Cardona1
1Cardio-Oncology Center of Excellence, Washington University School of Medicine, St Louis Mo.
Insights
Cardiac amyloidosis, a cause of heart failure, is often diagnosed late. Early recognition and treatment are crucial for better outcomes with new therapies, especially for primary care providers.
Area of Science:
- Cardiology
- Internal Medicine
- Medical Diagnostics
Background:
- Cardiac amyloidosis is an underdiagnosed cause of heart failure.
- Diagnostic delays can exceed 3 years, involving multiple specialist referrals.
- New therapies are most effective when initiated early in disease progression.
Purpose of the Study:
- To increase awareness of cardiac amyloidosis among primary care providers.
- To provide practical guidance on recognizing and diagnosing cardiac amyloidosis.
- To facilitate earlier diagnosis and treatment of cardiac amyloidosis.
Main Methods:
- Review of epidemiology, clinical manifestations, and diagnostic evaluation.
- Discussion of treatment strategies for transthyretin and light chain cardiac amyloidosis.
- Focus on practical guidance for primary care settings.
Main Results:
- Significant diagnostic delays are common in cardiac amyloidosis.
- Early diagnosis is essential for effective treatment with newly available therapies.
- Improved primary care provider awareness is key to timely intervention.
Conclusions:
- Earlier recognition of cardiac amyloidosis by primary care providers is essential.
- Timely diagnosis improves patient outcomes through prompt treatment initiation.
- This review aims to equip primary care providers with knowledge for earlier disease detection.
Abstract:
Cardiac amyloidosis is increasingly recognized as an underdiagnosed cause of heart failure. Diagnostic delays of up to 3 years from symptom onset may occur, and patients may be evaluated by more than 5 specialists prior to receiving the correct diagnosis. Newly available therapies improve clinical outcomes by preventing amyloid fibril deposition and are usually more effective in early stages of disease, making early diagnosis essential. Better awareness among primary care providers of the clinical presentation and modern treatment landscape is essential to improve timely diagnosis and early treatment of this disease. In this review, we provide practical guidance on the epidemiology, clinical manifestations, diagnostic evaluation, and treatment of transthyretin and light chain cardiac amyloidosis to promote earlier disease recognition among primary care providers.
More Related Videos
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Acute Coronary Syndrome III: Diagnostic Studies
Cardiomyopathy VI: Nursing Management
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy I: Introduction and Classification

